BeyondSpring Inc. (BYSI)

In the past six months, BeyondSpring's stock has experienced several notable events. The stock price increased by 20.00% in the month leading up to March 30, 2026, and by 12.50% over the last 12 months, though it had a year-to-date return of -0.61% as of March 30, 2026. The stock traded at $1.60 per share as of March 27, 2026. Its 52-week high was $3.44 and its 52-week low was $0.98. Key financial and clinical updates have impacted the stock. BeyondSpring reported its Q3 2025 financial results on November 12, 2025, and its 2025 year-end financial results on March 25, 2026. The 2025 year-end report highlighted positive Phase 3 results for Plinabulin in EGFR wild-type NSCLC, showing a statistically significant overall survival benefit and a reduction in grade 4 neutropenia. Despite these clinical advancements, the company reported ongoing operating losses and a net loss of $14.2 million in 2025, with limited cash from continuing operations, indicating a need for additional funding.

As a clinical-stage biopharmaceutical company, BeyondSpring Inc. does not generate revenue from product sales in the traditional sense. Its financial performance is primarily driven by research and development activities, clinical trial milestones, and strategic partnerships rather than seasonal consumer demand for products. Therefore, traditional demand seasonality for its products and services is not applicable.

BeyondSpring, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing innovative therapies for unmet medical needs, primarily in oncology and hematology. The company's core focus is on novel drug candidates that utilize cutting-edge research in areas such as protein degradation and immune modulation. Its major product pipeline revolves around Plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), in late-stage clinical development as an anti-cancer agent and for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring is also developing Plinabulin in combination with other immuno-oncology agents and chemotherapy and has a Targeted Protein Degradation (TPD) platform.

BeyondSpring Inc. is headquartered in Florham Park, New Jersey, United States. The company is actively developing treatments and conducting trials in both the United States and China, indicating a global development strategy and operational footprint across these regions.

In the past year, BeyondSpring's brand reputation has been influenced by its clinical trial progress and financial situation. Positive developments include the publication of favorable DUBLIN-3 Phase 3 study results for Plinabulin in The Lancet Respiratory Medicine and presentations at major conferences. The progress of its subsidiary, SEED Therapeutics, also contributes positively. However, the company's financial challenges, including ongoing operating losses and a limited cash runway, could negatively impact its reputation among investors.

BeyondSpring Inc. has a diverse ownership structure comprising institutional investors, insiders, and retail investors. Approximately 14.84% of the stock is held by institutional shareholders, 12.00% by BeyondSpring insiders, and 73.15% by retail investors. Major institutional owners include Decheng Capital LLC, Vanguard Group Inc., BlackRock, Inc., and others, with Decheng Capital LLC noted as the largest institutional holder. Decheng Capital China Life Sciences Usd Fund III LP is the largest individual shareholder, owning 4.03 million shares, representing 9.99% of the company.